Edwards Lifesciences Corporation
EW · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,553,100 | $1,532,200 | $1,412,700 | $1,385,800 |
| % Growth | 1.4% | 8.5% | 1.9% | – |
| Cost of Goods Sold | $345,200 | $342,600 | $301,600 | $292,200 |
| Gross Profit | $1,209,600 | $1,189,600 | $1,111,100 | $1,093,600 |
| % Margin | 77.9% | 77.6% | 78.7% | 78.9% |
| R&D Expenses | $280,700 | $276,200 | $254,600 | $271,100 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $514,600 | $502,000 | $465,700 | $491,900 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$10,800 | -$19,500 | -$4,000 | $18,000 |
| Operating Expenses | $784,500 | $758,700 | $716,300 | $781,000 |
| Operating Income | $425,100 | $430,900 | $394,800 | $312,600 |
| % Margin | 27.4% | 28.1% | 27.9% | 22.6% |
| Other Income/Exp. Net | -$76,700 | -$30,700 | $39,100 | $77,500 |
| Pre-Tax Income | $348,400 | $400,200 | $433,900 | $390,100 |
| Tax Expense | $56,100 | $64,300 | $70,300 | $45,100 |
| Net Income | $291,100 | $329,800 | $358,000 | $385,600 |
| % Margin | 18.7% | 21.5% | 25.3% | 27.8% |
| EPS | 0.5 | 0.57 | 0.61 | 0.65 |
| % Growth | -12.3% | -6.6% | -6.2% | – |
| EPS Diluted | 0.5 | 0.56 | 0.61 | 0.65 |
| Weighted Avg Shares Out | 584,700 | 587,000 | 586,900 | 589,800 |
| Weighted Avg Shares Out Dil | 585,700 | 587,900 | 587,800 | 590,500 |
| Supplemental Information | – | – | – | – |
| Interest Income | $38,600 | $37,400 | $19,500 | $44,200 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $39,200 | $38,100 | $36,600 | $42,600 |
| EBITDA | $387,600 | $400,200 | $470,500 | $483,700 |
| % Margin | 25% | 26.1% | 33.3% | 34.9% |